A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
adult patients, ≥ 18 years of age;
moderate to severe active rheumatoid arthritis (Disease Activity Score (DAS28) \> 4.4);
inadequate response to methotrexate;
on a stable dose of ≥ 15mg/week methotrexate for at least 6 weeks.
You may not be if
prior treatment with a biologic;
Rheumatoid arthritis (RA) functional class IV;
known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections;
evidence of active malignant disease.
Clareo Health | A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment
